Late-Breaking Clinical Results From The INSPIRE Study Revealed At The ERS Annual Congress In Stockholm

The INSPIRE (Investigating New Standards for Prophylaxis in Reduction of Exacerbations) study is a multi-centre, multinational, randomised, double-blind controlled trial which enrolled over 1′300 patients with severe or very severe COPD. It is the first large prospective study to compare the impact of two different treatments approaches, using either salmeterol/fluticasone propionate (SFC) or tiotropium bromide, in COPD exacerbations (sudden worsening of symptoms) over two years. [click link for full article]

More: continued here

Filed under: Clinical Trials on September 20th, 2007